Clinical Pharmacology Expert
Boehringer Ingelheim
Sebastan Haertter is currently Clinical Pharmacology Expert at Boehringer Ingelheim (BI). He is further member of Cardiometabolism Therapeutic Area leading bodies at BI. SH is also representative of Translational Science and Clinical Pharmacology in the BI Clinical Pediatric Expert Group, the Global Labeling and Risk/Benefit Committee, and Inlicensing expert groups.
SH is member of the IQ-Clin Pharm Leader Group (CPLG), past chair of the IQ-CPLG Pediatrics Working Group (WG) and the Exploratory Trial Design WG and current chair of WGs dealing with Disease as factor for PK variability (Disease affecting PK) and an IQ WG in support of the FDA ROADMAP TO 2030 FOR NEW DRUG EVALUATION IN OLDER ADULTS
SH is pharmacist by training, received his PhD in pharm chemistry and a lecturing degree (German Habilitation) in Pharmacology&Toxicology. He was in the past assistant professor at the University of Mainz (Germany), Adjunct Professor at the Universities of Ulm (Germany), Connecticut and Albany, NY and is author or co-author of > 100 peer reviewed publications.
He served as PhRMA deputy topic lead for ICH M9-Working Group, is currently EFPIA topic lead in the ICH M13 (Bioequivalence) Working Group and member of the EFPIA expert group in support of ICH M12 – DDI.
Disclosure information not submitted.
Thursday, May 12, 2022
8:00 AM – 12:00 PM ET
.png)